文献速递前列腺增生与排尿功能障碍

米拉贝隆与索利那新联用治疗膀胱过度活动症的叠加效应定量评估:SYNERGY研究再分析

Quantitative Assessment of Additive Effects of Mirabegron and Solifenacin in Overactive Bladder: Re-analysis of SYNERGY Study.
PubMed 文献 · Urology · 2026-07-15

该研究对SYNERGY研究进行事后定量再分析,采用基于高斯Copula的独立药物作用框架,比较索利那新单药、米拉贝隆单药及两药联合(S5+M25、S5+M50)的疗效。结果显示,联合治疗在各终点上的观察缓解率均落在IDA预测范围内,连续终点叠加指数接近1.0,患者报告结局亦呈叠加模式,未超出叠加预期。结论认为联合疗效可由叠加性独立药物作用解释,临床价值在于叠加症状控制且耐受性保持,而非协同作用。

要点

  • 联合治疗观察缓解率均落在IDA预测范围内,未超出叠加预期。
  • 连续终点叠加指数接近1.0,患者报告结局PRR为85%-94%。
  • 临床价值在于叠加症状控制且耐受性保持,而非协同作用。

核心结论

  • 米拉贝隆联合索利那新治疗OAB的疗效可由叠加性独立药物作用解释,而非协同作用。
  • 临床价值在于叠加症状控制且耐受性保持。

研究设计与样本

  • SYNERGY研究的事后定量再分析,比较索利那新单药、米拉贝隆单药及联合方案S5+M25和S5+M50。
  • 采用基于高斯Copula的独立药物作用框架建模两种单药治疗间的相关反应倾向。
  • 共同主要终点为零急迫性尿失禁(Zero UI)和排尿频率正常化(<8/24小时)。
  • 同时评估连续终点和患者报告结局(OAB-q、健康相关生活质量、PPBC)。
  • 通过预测缓解率(PRR)和叠加指数在广泛相关性假设下评估观察效应与IDA预测效应的一致性。

主要发现

  • S5+M50组Zero UI观察缓解率为50.7%,PRR为62.4%,分解为索利那新单独21.1%、米拉贝隆单独19.5%、重叠缓解21.8%。
  • S5+M50组排尿频率正常化缓解率达52.2%(PRR 65.6%)。
  • S5+M25组Zero UI和正常化缓解率分别为51.3%(PRR 64.4%)和52.6%(PRR 63.3%)。
  • 观察缓解率在相关性参数ρ=0.79-0.87范围内均落在IDA预测区间内。
  • 两种剂量方案的连续终点叠加指数均接近1.0,患者报告结局PRR为85%-94%,无终点超出叠加预期。

关键数值与推荐

  • S5+M50组Zero UI观察缓解率50.7%,PRR 62.4%。
  • S5+M50组排尿频率正常化缓解率52.2%,PRR 65.6%。
  • S5+M25组Zero UI缓解率51.3%(PRR 64.4%),正常化缓解率52.6%(PRR 63.3%)。
  • IDA预测相关性参数范围ρ=0.79-0.87。
  • 连续终点叠加指数接近1.0,患者报告结局PRR 85%-94%。

临床怎么用

  • 联合用药的获益为叠加效应,临床决策时可预期症状叠加改善而非协同增效。
  • 联合方案在保持耐受性的同时提供叠加症状控制。

局限性

  • 本研究为SYNERGY研究的事后再分析。
  • 采用模型框架评估独立药物作用,相关性假设范围ρ=0.79-0.87。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantitatively determine whether the clinical benefit of mirabegron plus solifenacin for overactive bladder (OAB) reflects pharmacological synergy or independent drug action. METHODS: We conducted a post hoc quantitative reanalysis of the SYNERGY study comparing solifenacin monotherapy, mirabegron monotherapy, and their combinations (S5+M25, S5+M50). A copula-based independent drug action (IDA) framework with a Gaussian copula was applied to model correlated response propensity between monotherapies. Co-primary endpoints were zero urgency urinary incontinence (Zero UI) and normalization of micturition frequency (<8/24hours). Continuous endpoints and patient-reported outcomes (OAB-q, health-related quality of life, PPBC) were also evaluated. Agreement between observed and IDA-predicted effects was assessed using predicted response rate (PRR) and additivity indices across a wide range of correlation assumptions. RESULTS: For S5+M50, the observed Zero UI responder rate was 50.7%, and PRR was 62.4%, decomposed into 21.1% solifenacin-only, 19.5% mirabegron-only, and 21.8% overlapping responders. Normalized micturition frequency responders reached 52.2% (PRR 65.6%). For S5+M25, Zero UI and normalization responder rates were 51.3% (PRR 64.4%) and 52.6% (PRR 63.3%), respectively. Observed responder rates consistently fell within IDA-predicted ranges across correlation parameters (ρ = 0.79-0.87). Continuous endpoints showed additivity indices close to 1.0 for both dose regimens. Patient-reported outcomes similarly demonstrated additive patterns, with PRRs of 85%-94% across OAB-q, quality-of-life, and PPBC measures. No endpoint exceeded additive expectations. CONCLUSION: The efficacy of mirabegron-solifenacin combination therapy in OAB seems to be explained by additive IDA. Its clinical value lies in additive symptom control with preserved tolerability rather than synergistic interaction.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chen W, Yoshida S, Yajima S, et al. Quantitative Assessment of Additive Effects of Mirabegron and Solifenacin in Overactive Bladder: Re-analysis of SYNERGY Study. Urology. 2026. PMID: 42456778. doi:10.1016/j.urology.2026.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。